| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |